Skip to main content

Table 1 Clinical characteristics of childhood acute leukaemia patients involved in discovery and validation cohorts

From: MicroRNA-181a as novel liquid biopsy marker of central nervous system involvement in pediatric acute lymphoblastic leukemia

Total number of examined samples

Samples

Discovery cohort

Validation cohort

20

138

Control group (sample type, number of individuals)

PB, n = 10

CSF, n = 6

ID

Diagnosis, treatment

CSF cytology (CNS status according to protocol)

CSF

CSF

BM

PB

CNS+ patient group

 P1

ALL, late-onset Relb

lymphoid cells with unambiguous blasts (CNS-2)

d0

d0, d15

d0, d15, d30

d0, d15, d30

 P2

ALL, de novoc

86 WBCs; high amount of blasts (CNS-3)

d0, d15

d0, d15, d32, d45

d37

d0, d37

 P3

ALL, de novoa

1 unambiguous blast, 2 suspicious cells (CNS-2)

d0

d0, d15, d33

d0, d15, d33

d0, d15, d33

 P4

ALL, de novoa

4 WBCs/μl with blasts (CNS-2)

d0, d15

 P5

ALL, de novoa

18 lymphoid cells (mainly blasts), 20 Gumprecht shadows (CNS-2)

d0, d15

d0, d15

d0, d15

 P6

ALL, de novoa

1 unambiguous blast (CNS-2)

d0, d15, d33

d0, d15, d33

d0, d15, d33

 P7

MPAL, de novoa

some cells, 70% blast (CNS-2)

d15, d33

d0, d15, d33

d0, d15, d33

 P8

AML, de novod

53 cells; 8% blast (CNS-2)

d0, d15

d0

d0, d15

 P9

AML, de novod

7 WBCs/μl; numerous blasts (CNS-3)

d0, d28

d0, d28

d0, d28

 P10

ALL, early-onset Relb

43 WBCs, mostly blasts (CNS-3)

d0

d0

 P11

ALL, de novoa

nucleated cells, 70% blast (CNS-2)

d0, d15

 P12

ALL, de novoa

35 lymphoid cells with 10% blast (CNS-2)

d0, d15, d26, d40

CNS patient group

 P13

ALL, de novoa

1 cell/μl without blasts (CNS-1)

d0

 P14

ALL, de novoa

without cells (CNS-1)

d0

 P15

ALL, de novoa

without cells (CNS-1)

d0

 P16

ALL, de novoa

1 cell/μl without blasts (CNS-1)

d0

 P17

ALL, early-onset Relb

squamous cells, 2 lymphocyte, 1 Gumprecht shadow (CNS-1)

d0, d15

d0, d15, d37

d0, d15, d37

 P18

ALL, early-onset Relb

without cells (CNS-1)

d0, d15

d0, d15

d0, d15

 P19

ALL, de novoa

without cells (CNS-1)

d0, d15, d33

d0, d15, d33

d0, d15, d33

 P20

ALL, de novoa

only a few RBCs (CNS-1)

d0, d15

d0, d15, d33

d0, d15, d33

 P21

ALL, de novoa

2 cells without blasts (CNS-1)

d0, d15, d33

d0, d15, d33

d0, d15, d33

 P22

MPAL, de novoa

a few squamous cells on cytospin (CNS-1)

d15, d38

d0, d15, d38

d0, d15, d38

 P23

AML, de novod

some RBCs without blasts (CNS-1)

d0

d0, d23

d0, d15, d23

 P24

AML, de novod

1 segmented, 2 band neutrophil granulocytes (CNS-1)

d0, d28

d0, d15, d28

d28

 P25

ALL, de novoa

1 segment, 8 WBC (CNS-1)

d0

d0

 P26

ALL, de novoa

without cells (CNS-1)

d0

 P27

ALL, de novoa

without cells (CNS-1)

d0

 P28

ALL, de novoa

4 segmented neutrophil cells, 3 lymphocytes, 1 monocyte, 1 Gumprecht shadow, but no blasts (CNS-1)

d0

 P29

ALL, de novoa

without cells (CNS-1)

d0

  1. Treatment guidelines: aALL IC BFM 2009, bALL REZ BFM 2002, cInterfant 2006, dAML BFM 98
  2. CNS central nervous system, ALL acute lymphoblastic leukaemia, AML acute myeloid leukaemia, MPAL mixed phenotype acute leukaemia, Rel relapse, CSF cerebrospinal fluid, BM bone marrow, PB peripheral blood, WBC white blood cell, RBC red blood cell, d day